| NCT ID | NCT02877303 |
| Title | Blinatumomab and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | M.D. Anderson Cancer Center |
| Indications |
childhood B-cell acute lymphoblastic leukemia |
| Therapies |
Blinatumomab + Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Blinatumomab + Mercaptopurine + Methotrexate + Prednisone + Vincristine Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Vincristine Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Rituximab + Vincristine |
| Age Groups: | child senior adult |